Renal Nuclear Medicine

Radiopharmaceuticals - Kidney's Glow‑Up Drugs

• Overview: Choice of agent depends on the specific renal function or anatomy to be assessed.

Dynamic Scintigraphy - Kidney Flow Show

• Assesses renal perfusion, parenchymal function (uptake), and urinary excretion.
  • 99mTc-DTPA: Glomerular filtration. GFR via Gates method, e.g., $GFR \propto \frac{Kidney Counts}{Plasma Activity}$.
  • 99mTc-MAG3: Tubular secretion (ERPF), preferred in ↓ renal function.
• Procedure: Ensure patient hydration, IV tracer injection, dynamic imaging (0-30 min).
• Renogram Curve Phases:
  • Phase 1 (Vascular/Perfusion): 0-60s; rapid initial rise (blood flow).
  • Phase 2 (Cortical/Concentration): 1-5 min; slower rise to peak activity (Tmax 3-5 min).
  • Phase 3 (Excretion/Drainage): >5 min; progressive downslope (washout). T1/2 excretion <15-20 min (post-diuretic if applicable).
• Key Parameters: Differential Renal Function (DRF), Tmax, T1/2 excretion time.
• Uses: Suspected obstruction (diuretic scan), renovascular hypertension (captopril scan), renal transplant evaluation.

⭐ The second phase of the renogram primarily reflects tracer uptake by the renal tubules for agents like MAG3. oka

Static & Diuretic Scans - Structure & Blockage Busters

• Static Renal Scintigraphy (DMSA Scan)

  • Agent: Technetium-99m DMSA ($^{99m}$Tc-DMSA); imaging at 2-4 hours.
  • Primary use: Evaluate renal cortical integrity, detect/localize scars (e.g., post-pyelonephritis), assess split renal function (SRF), identify ectopic kidneys.
  • Mechanism: Binds to megalin in proximal convoluted tubules.
  • 

  ⭐ Tc-99m DMSA is the gold standard for detecting and localizing renal cortical scars.

• Diuretic Renography (MAG3/DTPA Scan)

  • Agents: $^{99m}$Tc-MAG3 (preferred for higher extraction efficiency, better in impaired renal function) or $^{99m}$Tc-DTPA.
  • Purpose: Differentiate obstructive from non-obstructive dilatation of pelvicalyceal system.
  • Procedure: Furosemide (e.g., 0.5-1 mg/kg) given when pelvis is full of tracer.
  • Interpretation (Washout half-time, T1/2, post-furosemide):
    • Non-obstructed: T1/2 < 10 min
    • Indeterminate/Equivocal: T1/2 10-20 min
    • Obstructed: T1/2 > 20 min

• Diuretic Renography Interpretation

Special Applications - Hypertension & Transplants

Hypertension (RVH): Captopril Renography

• Detects hemodynamically significant Renal Artery Stenosis (RAS).
• Agents: $99mTc$-DTPA (GFR), $99mTc$-MAG3 (ERPF).
• Captopril (ACE-I) ↓ GFR in stenotic kidney.
• Positive (DTPA): GFR ↓ >20%, Tmax ↑, SRF ↓ >10%.
• Positive (MAG3): Marked cortical retention, Tmax ↑.

⭐ Positive captopril renography: high likelihood of hemodynamically significant RAS.

Renal Transplant Evaluation

• Baseline: 24-48 hrs post-op.
• Key differentiators:
  • ATN: Good perfusion, poor excretion (early post-op).
  • Acute Rejection: ↓ Perfusion, ↓ uptake, ↓ excretion (after 1st week).
  • Obstruction: Diuretic renography (Furosemide) T1/2 > 20 min.
• Urine leak: Extravasation of tracer.

High‑Yield Points - ⚡ Biggest Takeaways

• DTPA is primarily for GFR estimation and assessing renal perfusion.
• MAG3 is preferred for ERPF estimation and evaluating tubular function.
• DMSA is the agent of choice for renal cortical imaging, identifying scars and acute pyelonephritis.
• Captopril renography is crucial for diagnosing renovascular hypertension by unmasking RAS.
• Diuretic renography (e.g., Furosemide) differentiates obstructive from non-obstructive hydronephrosis.
• Direct Radionuclide Cystography (DRCG) is sensitive for detecting Vesicoureteral Reflux (VUR).